Form 4: Timothy A. Springer Reports Purchase of Cartesian Therapeutics Shares

Director and 10% owner Timothy A. Springer reports purchasing 19,044 shares of Cartesian Therapeutics at an average price of $0.5985 on March 18, 2024.

Summary

• On March 18, 2024, Timothy A. Springer, a director and 10% owner of Cartesian Therapeutics, Inc. (RNAC), purchased 19,044 shares of common stock at an average price of $0.5985 per share.
• The shares were bought in multiple transactions with prices ranging from $0.575 to $0.60.
• Following the transaction, Springer directly owns 7,471,625 shares and indirectly owns 31,073,406 shares through TAS Partners LLC and 86,418 shares through his wife.
• Springer is the managing member of TAS Partners LLC and disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of a share purchase by a company insider. While insider buying can be seen as positive, it's a single transaction and doesn't provide enough information to strongly indicate a positive outlook.

Positives

• The purchase of shares by a director and significant owner could be interpreted as a sign of confidence in the company's future prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders of a publicly traded company buy or sell the company's securities. This provides transparency to the market regarding the actions of company insiders.

Stakeholder Impact

• The purchase of shares by a director may have a slightly positive impact on shareholder confidence.

Key Dates